CAH

Rating neutralTentativeAI MemoPost-earnings T+3

Cardinal Health

As of 2026-08-14/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

FY26 mixed earnings outcome with FY27 EPS guide reset • 2026-08-11

Base target: $250 / p=50% prob

Biggest risk

Q4 headline non-GAAP EPS benefited from a one-time tariff-refund contribution, while revenue was below the preprint estimate in the packet. The key downside risk is guidance de-rating if specialty momentum, medical distribution, or margin execution weakens.

Invalidation

Break below $205 or thesis failure.

What would change my mind?

The official FY27 guide implies durable double-digit EPS growth, while FY26 showed broad-based segment profit gains and strong cash generation. The new repurchase authorization adds support if execution holds [#SEC-8K-2026-08-11].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-14

Base target

$250

p=50%

Bull target

$280

p=25%

Bear target

$205

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print digestion of mixed revenue quality
Broad-based profit execution and capital returns
The official FY27 guide implies durable double-digit EPS growth, while FY26 showed broad-based segment profit gains and strong cash generation.

BearKey bullets

FY27 guidance must absorb ongoing pricing, tariff, volume, and execution risks.
Post-print analyst revisions, target changes, and detailed consensus updates are unavailable in the packet.
Prior-quarter evidence showed Global Medical Products and Distribution profit down 36% on lower distribution volumes [#SEC-8K-2026-04-30].

WatchKey bullets

FY26 mixed earnings outcome with FY27 EPS guide reset

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $250 (p=50%)

Target spread vs base: +12% / -18%

Scenario probabilities

Bull Target: $280 (p=25%)Base Target: $250 (p=50%)Bear Target: $205 (p=25%)

Commentary

Post-earnings tone is mildly constructive: the company delivered strong EPS growth and above-long-term FY27 guidance, while an Investor's Business Daily headline said the shares ticked higher despite a mixed quarter. The exact post-release price move is unavailable, and the packet contains no post-print analyst revisions or target changes, so this remains a constructive monitoring view rather than a high-conviction bullish signal.

As of 2026-08-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print digestion of mixed revenue quality
Broad-based profit execution and capital returns

Scenarios

Bull Target (Scenario probability)

$280 / p=25% prob

Base Target (Scenario probability)

$250 / p=50% prob

Bear Target (Scenario probability)

$205 / p=25% prob

Analysis 2026-08-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.58

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-08-11
FY26 mixed earnings outcome with FY27 EPS guide reset
The official release reported Q4 FY26 revenue of $63.7 billion and non-GAAP diluted EPS of $2.91. Against the packet's preprint Zacks estimates of $65.61 billion revenue and $2.42 EPS, this indicates a mixed top-line/EPS result; Cardinal Health then guided FY27 non-GAAP EPS to $12.40-$12.60, representing 13%-15% growth and exceeding its long-term framework [#SEC-8K-2026-08-11].
Prob 78.00% • Move 5.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Post-print digestion of mixed revenue quality
2026-08-14
Investors must weigh the Q4 earnings outcome against revenue growth of 6% and a $100 million one-time IEEPA tariff-refund benefit included in non-GAAP earnings. Near-term sentiment may remain sensitive to how much of the FY27 outlook is recurring versus benefit-driven [#SEC-8K-2026-08-11].
Prob 60% • Move -3% • Priced-in 50%

Long-term Catalysts

Months to a year

Broad-based profit execution and capital returns
2027-08-14
FY26 profit growth extended across all five operating segments, with $5.2 billion of operating cash flow, $5.0 billion of adjusted free cash flow, $1.4 billion of repurchases, and a new $5.0 billion authorization. Sustaining this execution is the main longer-term upside case [#SEC-8K-2026-08-11].
Prob 65% • Move 9% • Priced-in 55%

Risks

FY27 guidance must absorb ongoing pricing, tariff, volume, and execution risks.
Post-print analyst revisions, target changes, and detailed consensus updates are unavailable in the packet.
Prior-quarter evidence showed Global Medical Products and Distribution profit down 36% on lower distribution volumes [#SEC-8K-2026-04-30].
Q4 non-GAAP earnings included a one-time $100 million IEEPA tariff-refund benefit.
The peer set lacks a second direct public pharmaceutical-distribution comparator.

Peers

Symbol	Summary
COR	Closest public operating peer in pharmaceutical distribution and specialty services; CAH's favorable relative case depends on sustaining specialty profit momentum without margin giveback.
BDX	Same-sector healthcare comparator with a different business mix and not a direct distributor peer. The packet does not provide a second comparably direct public operating comparator, so relative valuation conclusions remain limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-14

Loading AI feed…

Symbol

Summary

COR

Closest public operating peer in pharmaceutical distribution and specialty services; CAH's favorable relative case depends on sustaining specialty profit momentum without margin giveback.

BDX

Same-sector healthcare comparator with a different business mix and not a direct distributor peer. The packet does not provide a second comparably direct public operating comparator, so relative valuation conclusions remain limited.